DLST

DLST encodes the dihydrolipoyl succinyltransferase (E2) core component of the α-ketoglutarate dehydrogenase complex, catalyzing conversion of α-ketoglutarate to succinyl-CoA in the TCA cycle; disruption of its yeast ortholog KGD2 abolishes mitochondrial NAD+ reduction by α-ketoglutarate, establishing its essential catalytic role (PMID:2115121). Through this activity DLST controls TCA flux and the downstream supply of NADH for oxidative phosphorylation: depletion arrests TCA cycle progression with α-KG accumulation and loss of succinyl-CoA, and the resulting energetic and metabolic defects drive apoptosis that is rescued by downstream intermediates such as succinate (PMID:26876595, PMID:34233924). This DLST-dependent energy supply is physiologically required, exemplified by defective cardiac pacemaker excitation and reduced ATP in DLST-deficient zebrafish (PMID:25697682). In cancer contexts DLST is a metabolic dependency: it sustains NADH/OXPHOS and proliferation in MYCN-amplified neuroblastoma and T-ALL (PMID:26876595, PMID:34233924), regulates ROS homeostasis in triple-negative breast cancer (PMID:34785772), and acts upstream of p38 MAPK signaling in osteosarcoma (PMID:41616466). Pathogenic germline DLST variants impair enzyme activity and cause accumulation of the oncometabolite 2-hydroxyglutarate with attendant DNA hypermethylation in pheochromocytoma-paraganglioma (PMID:30929736, PMID:33180916). DLST levels are set both transcriptionally, through EPC1/2-mediated histone H3 acetylation acting with SRF and FOXR2 to drive hematopoietic progenitor emergence (PMID:38439957), and post-translationally, through Grpel2-assisted mitochondrial import (PMID:36927450) and lncRNA-mediated protection from ubiquitin-dependent degradation (PMID:40634956). The DLST locus is bifunctional, additionally producing a truncated intermembrane-space protein (MIRTD) required for biogenesis of respiratory complexes I and IV (PMID:12805207), and alternative splicing yields a ~30 kDa myofibrillar I-band isoform (PMID:19819302).

1. 1990 High

   Established that DLST's ortholog is the catalytic E2 subunit of the α-ketoglutarate dehydrogenase complex and is indispensable for complex activity, defining its core biochemical function.

   Evidence Chromosomal KGD2 disruption with biochemical complementation assay and sequence analysis in yeast

   PMID:2115121

   Open questions at the time

   • Performed in yeast ortholog, not human DLST
   • Structural basis of catalysis not resolved
   • Regulation of complex assembly not addressed
2. 1990 High

   Showed the gene's transcription is under nutrient/catabolite control via HAP2/HAP3 activators, linking expression to respiratory metabolic demand.

   Evidence lacZ promoter fusions, deletion mapping, and Northern blot in hap2/hap3 mutant yeast

   PMID:2115121

   Open questions at the time

   • HAP-element regulation demonstrated only in yeast
   • Human transcriptional control not addressed here
3. 2003 High

   Revealed the DLST locus is bifunctional, encoding a distinct intermembrane-space protein (MIRTD) needed for respiratory complex I and IV biogenesis beyond the matrix E2 enzyme.

   Evidence Novel transcript cloning, immunolocalization, and maxizyme-mediated MIRTD knockdown with respiratory complex readouts in SH-SY5Y cells

   PMID:12805207

   Open questions at the time

   • Molecular mechanism by which MIRTD supports complex assembly unknown
   • Interaction partners of MIRTD not identified
4. 2009 Medium

   Identified a non-mitochondrial myofibrillar I-band isoform produced by alternative splicing, indicating tissue-specific functional diversification.

   Evidence Immunocytochemistry, protein purification with sequencing, and cDNA isolation of splice variants in rat skeletal muscle

   PMID:19819302

   Open questions at the time

   • Function of the I-band isoform unknown
   • Demonstrated in rat only
   • No catalytic or structural role established
5. 2015 High

   Connected DLST-dependent TCA activity to organ physiology by showing its loss reduces ATP and impairs cardiac pacemaker excitation.

   Evidence Positional cloning, morpholino knockdown, electrical pacing rescue, and ATP measurement in zebrafish embryos

   PMID:25697682

   Open questions at the time

   • Mechanism linking ATP deficit to pacemaker excitation not fully resolved
   • Tissue-specific dependency not dissected
6. 2016 High

   Placed DLST as a metabolic dependency in cancer, defining its pathway position via metabolite epistasis where downstream succinate rescues loss-of-function.

   Evidence RNAi, polar metabolomics, viability/apoptosis assays, metabolite rescue, and zebrafish genetic model in T-ALL

   PMID:26876595

   Open questions at the time

   • Selectivity of T-ALL dependence vs normal cells not fully defined
   • Mechanism of apoptosis induction not specified
7. 2019 High

   Linked impaired DLST enzyme function to oncometabolite (2-hydroxyglutarate) accumulation and pseudohypoxic epigenetic reprogramming in hereditary tumors.

   Evidence Targeted sequencing, 13C5-glutamate tracing, metabolite and methylation/expression profiling, and heterologous functional assay in pheochromocytoma-paraganglioma

   PMID:30929736

   Open questions at the time

   • Enzymatic route from DLST deficiency to 2-HG production not mechanistically detailed
   • Causality of methylation changes for tumorigenesis not proven
8. 2021 High

   Distinguished DLST's primary cancer-relevant output as NADH/OXPHOS support rather than broad TCA metabolite supply in MYCN-amplified neuroblastoma.

   Evidence shRNA depletion, NADH and OXPHOS assays, metabolomics, zebrafish and mouse xenograft tumor models

   PMID:34233924

   Open questions at the time

   • Why only α-KG accumulates among TCA intermediates unexplained
   • Generality across non-MYCN tumors not tested
9. 2021 Medium

   Established DLST control of ROS homeostasis as a determinant of cancer cell growth, with antioxidant rescue defining the link.

   Evidence RNAi, metabolomics, ROS measurement, and N-acetyl-L-cysteine rescue in triple-negative breast cancer cells

   PMID:34785772

   Open questions at the time

   • Source of elevated ROS upon DLST loss not pinpointed
   • Partial rescue indicates additional mechanisms
10. 2021 Medium

    Confirmed specific germline DLST variants directly reduce enzyme activity and drive DNA hypermethylation in patient-derived and engineered systems.

    Evidence Functional enzyme activity assays, DNA methylation profiling, and engineered variant cell lines

    PMID:33180916

    Open questions at the time

    • Single lab
    • Mechanistic chain from activity loss to methylation not fully reconstituted
11. 2023 Medium

    Identified Grpel2 as a physical partner mediating glucose-dependent mitochondrial import of DLST, coupling import to cardiomyocyte protection.

    Evidence Reciprocal Co-IP, DLST siRNA, mitochondrial ROS/respiration/membrane potential assays, and AAV9 mouse model of diabetic cardiomyopathy

    PMID:36927450

    Open questions at the time

    • Direct vs indirect Grpel2-DLST contact not structurally resolved
    • Single lab
12. 2024 Medium

    Defined an EPC1/2–histone H3 acetylation axis that transcriptionally activates DLST with SRF and FOXR2 to support hematopoietic stem and progenitor emergence.

    Evidence EPC1/2 depletion, ChIP for H3 acetylation at the DLST locus, HSPC quantification in zebrafish, and K562 expression profiling

    PMID:38439957

    Open questions at the time

    • Direct binding of SRF/FOXR2 to DLST regulatory regions not fully mapped
    • Whether DLST metabolic output mediates HSPC effect not proven
13. 2025 Medium

    Revealed post-translational stabilization of DLST by a HIF-1α-induced lncRNA that blocks its ubiquitination, coupling hypoxia to DLST-driven therapy resistance.

    Evidence Co-IP of APCDD1L-AS1–DLST complex, ubiquitination assay, lncRNA knockdown/overexpression, HIF-1α ChIP, and in vivo resistance models in lung adenocarcinoma

    PMID:40634956

    Open questions at the time

    • E3 ligase targeting DLST not identified
    • Single lab
14. 2026 Medium

    Positioned DLST upstream of p38 MAPK signaling as the route by which it promotes osteosarcoma malignancy.

    Evidence siRNA knockdown, RNA-seq, pharmacological p38 MAPK inhibition rescue, migration/invasion assays, and animal tumor model

    PMID:41616466

    Open questions at the time

    • Molecular connection between DLST metabolism and p38 activation unknown
    • Single lab

• Whether DLST has a moonlighting nuclear, chromatin-modifying role via histone succinylation remains to be functionally established.
• Preprint, not peer-reviewed
• No direct functional manipulation of DLST tying nuclear localization to histone succinylation
• Causality for myogenesis impairment not demonstrated